Future Journal of Pharmaceutical Sciences最新文献

筛选
英文 中文
Investigating the clinical outcomes of prolonged versus intermittent infusion of meropenem in critically ill pediatric patients: a randomized double-blind single-center study 研究危重儿科患者长期输注美罗培南与间歇输注美罗培南的临床结果:一项随机双盲单中心研究
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-16 DOI: 10.1186/s43094-026-00935-6
Rania Saad Mahmoud, Maher Mukhtar Ahmed, Sahar Badr Hassan, Mohamed Mahmoud Mohamed Abdel-Latif
{"title":"Investigating the clinical outcomes of prolonged versus intermittent infusion of meropenem in critically ill pediatric patients: a randomized double-blind single-center study","authors":"Rania Saad Mahmoud,&nbsp;Maher Mukhtar Ahmed,&nbsp;Sahar Badr Hassan,&nbsp;Mohamed Mahmoud Mohamed Abdel-Latif","doi":"10.1186/s43094-026-00935-6","DOIUrl":"10.1186/s43094-026-00935-6","url":null,"abstract":"<div><h3>Background</h3><p>Optimal antibiotic dosing strategies, such as prolonged infusion (PI), are hypothesized to improve clinical outcomes in critically ill patients by maximizing time above the minimum inhibitory concentration. This prospective study aimed to evaluate whether PI of meropenem enhances clinical outcomes and reduces mortality compared to standard intermittent infusion (II) in pediatric patients diagnosed with culture-negative sepsis in the pediatric intensive care unit (PICU).</p><h3>Methods</h3><p>A prospective, double-blind, randomized, clinical study was conducted in PICU between May 2019 and November 2019 aimed to evaluate whether PI of meropenem enhances clinical outcomes and reduces mortality in pediatric patients diagnosed with culture-negative sepsis. Eligible patients with culture-negative sepsis were assigned to receive meropenem as either a 3-h PI or a 30-min II administered at a dose of 60 mg/kg/day every 8 h. The primary endpoint was clinical improvement that was defined as a reduction in the pediatric Sequential Organ Failure Assessment (pSOFA) score on the 7th day of meropenem therapy. Secondary outcomes included PICU mortality, C-reactive protein (CRP) level, and length of stay in the PICU.</p><h3>Results</h3><p>Baseline characteristics were comparable between the two groups (age, gender, CRP, and pre-treatment pSOFA score). By the 7th day of meropenem therapy, the PI group showed greater clinical improvement, as evidenced by a significantly lower pSOFA score compared to the II group [(median pSOFA score: 1; IQR (4)] versus [(median pSOFA score: 4; IQR: (9.75)] in II group (<i>p</i> = 0.008). The 14-day mortality rate in the PICU was lower among patients receiving PI compared to those treated with II (24.2% vs 57.1%, <i>p</i> &lt; 0.001). CRP showed a greater reduction in the PI compared to the II group (35% vs 105.25%, <i>p</i> = 0.028). Both groups did not differ significantly concerning PICU length of stay (<i>p</i> = 0.104). The ∆pSOFA score showed excellent predictive accuracy (AUC = 0.946) for early treatment response in critically ill pediatric patients, with a cutoff of − 2.5 yielding high sensitivity and specificity. Kaplan–Meier analysis demonstrated a statistically significant difference in survival between the two groups (log-rank <i>p</i> = 0.026), highlighting the impact of treatment strategy on patient outcomes.</p><h3>Conclusion</h3><p>PI of meropenem was associated with enhanced clinical improvement and reduced mortality rates in pediatric patients with culture-negative sepsis.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00935-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations 贝洛替康在卵巢癌抗炎潜能和纳米制剂的机制洞察
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-13 DOI: 10.1186/s43094-026-00940-9
Ajay Kumar, Gesu Singla,  Amita, Brahmjot Singh, Pooja Sharma, Sandeep Kaur, Poonam Chaturvedi, Bunty Sharma, Shafiul Haque, Hardeep Singh Tuli
{"title":"Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations","authors":"Ajay Kumar,&nbsp;Gesu Singla,&nbsp; Amita,&nbsp;Brahmjot Singh,&nbsp;Pooja Sharma,&nbsp;Sandeep Kaur,&nbsp;Poonam Chaturvedi,&nbsp;Bunty Sharma,&nbsp;Shafiul Haque,&nbsp;Hardeep Singh Tuli","doi":"10.1186/s43094-026-00940-9","DOIUrl":"10.1186/s43094-026-00940-9","url":null,"abstract":"<div><h3>Background</h3><p>Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.</p><h3>Main body</h3><p>This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.</p><h3>Conclusion</h3><p>This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00940-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147339033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The persistence of COVID-19 vaccine artifacts in bodily fluids and tissues: a systematic review 体液和组织中持续存在的COVID-19疫苗产物:系统综述
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-10 DOI: 10.1186/s43094-026-00939-2
Edgar Selem, Mikolaj Raszek, Joseph Varon, Matthew Halma
{"title":"The persistence of COVID-19 vaccine artifacts in bodily fluids and tissues: a systematic review","authors":"Edgar Selem,&nbsp;Mikolaj Raszek,&nbsp;Joseph Varon,&nbsp;Matthew Halma","doi":"10.1186/s43094-026-00939-2","DOIUrl":"10.1186/s43094-026-00939-2","url":null,"abstract":"<div><h3>Background</h3><p>Early assumptions about COVID-19 vaccine components suggested that modified messenger RNA and spike protein would be rapidly cleared from the body, consistent with the known degradation pathways of natural RNA. However, multiple studies have identified these vaccine-derived components in human tissues and bodily fluids for unexpectedly prolonged periods after vaccination. This persistence challenges initial expectations and raises important questions about the mechanisms enabling such long-term presence.</p><h3>Main body</h3><p>This review systematically examines the evidence for enduring COVID-19 vaccine components, including modified messenger RNA, spike protein, and lipid nanoparticles, in the human body long after administration. We evaluate the techniques used to detect these substances, highlighting the sensitivity and specificity of various assays, and summarize the specific tissues and fluids where these components have been found. Special attention is given to methodological considerations that may influence detection and interpretation. Furthermore, this review explores potential biological explanations for the prolonged presence of vaccine-derived material. Possible mechanisms include altered RNA stability due to chemical modifications, slow clearance of lipid nanoparticles, and the formation of stable complexes or reservoirs within tissues. The evidence for each hypothesis is discussed, with an emphasis on distinguishing between true persistence and assay artifacts.</p><h3>Conclusion</h3><p>The reported persistence of COVID-19 vaccine components in the body is a phenomenon that warrants deeper investigation. While methodological factors must be carefully considered, the available data suggest that certain vaccine derivatives may remain detectable for extended periods. Understanding the underlying mechanisms is important for assessing vaccine safety and optimizing future mRNA-based therapeutics.</p><h3>Graphic abstract</h3><p>Figure adapted Halma MTJ, Rose J, Lawrie T (2023) The Novelty of mRNA Viral Vaccines and Potential Harms: A Scoping Review. J 6:220–235. https://doi.org/10.3390/j6020017 under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).</p>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00939-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147338552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biochemical disturbances caused by ranitidine in rats: attention to bilirubin–lipids relation and benefits of capsiate 雷尼替丁引起的大鼠生化紊乱:对胆红素-脂质关系的关注及胶囊胶囊的益处
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-03 DOI: 10.1186/s43094-025-00932-1
Nawal Z. Haggag, Nora E. M. Shaheen, Amal A. Shahin, Eman S. Elhadidi, Eman A. Sherif
{"title":"Biochemical disturbances caused by ranitidine in rats: attention to bilirubin–lipids relation and benefits of capsiate","authors":"Nawal Z. Haggag,&nbsp;Nora E. M. Shaheen,&nbsp;Amal A. Shahin,&nbsp;Eman S. Elhadidi,&nbsp;Eman A. Sherif","doi":"10.1186/s43094-025-00932-1","DOIUrl":"10.1186/s43094-025-00932-1","url":null,"abstract":"<div><p>Ranitidine is an H2-receptor antagonist used to control acid disorders in the gastrointestinal tract. But the long-term use of ranitidine is related to liver dysfunction, which may alter bilirubin levels and disrupt lipid metabolism. Bilirubin, beyond being a liver function marker, plays a role against oxidative stress and lipid dysregulation. In this research, we set out to study the toxic outcomes of ranitidine in selected biochemical parameters with emphasis on the biochemical relationship between bilirubin dysregulation and lipid disturbances and to evaluate the therapeutic potential of capsiate in counteracting this disturbed relationship. The rats are grouped as follows: control, ranitidine-treated, capsiate-treated, and a combination of ranitidine with capsiate-treated group. Capsiate and ranitidine were orally given at doses of (60 mg/kg.b.wt and 300 mg/kg.b.wt, respectively). Body weight gain and liver weights and relative liver weights; serum levels of direct bilirubin, lipids, glucose, hematological parameters, electrolytes, and comet assay results were evaluated. Ranitidine causes metabolic disturbances, linked with bilirubin, lipids, and glucose regulation, and other biochemical assessments as well as genotoxicity. These findings give new insights about the biochemical link between bilirubin and lipid disturbances in ranitidine-induced liver alterations. On the other hand, capsiate mitigates the biochemical disturbances, genotoxicity, and modulate the disturbed relationship between bilirubin and lipids. The efficacy of capsiate to modulate these disturbances positions it as a promising candidate for future therapeutic applications.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00932-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147336507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biological modulation and repair using plant-derived bioactives: advancements in tissue engineering and regenerative medicine 利用植物源性生物活性进行生物调节和修复:组织工程和再生医学的进展
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-02 DOI: 10.1186/s43094-026-00933-8
Shymaa Hatem, Roxane Abdel-Gawad, Doha K. Hussein, Riham A. El-Shiekh, Eman A. Bseiso
{"title":"Biological modulation and repair using plant-derived bioactives: advancements in tissue engineering and regenerative medicine","authors":"Shymaa Hatem,&nbsp;Roxane Abdel-Gawad,&nbsp;Doha K. Hussein,&nbsp;Riham A. El-Shiekh,&nbsp;Eman A. Bseiso","doi":"10.1186/s43094-026-00933-8","DOIUrl":"10.1186/s43094-026-00933-8","url":null,"abstract":"<div><h3>Background</h3><p>The discipline of tissue engineering (TE) is experiencing significant advancements, characterized by both rapid progress and periods of slower development that sometimes fall short of earlier expectations. This review serves as a comprehensive inventory of achievements aimed at enhancing the innovation process within the field. Tissue engineering has embraced novel technologies and devised innovative methodologies for constructing tissue models, which are instrumental in studying and addressing various disease conditions.</p><h3>Methods</h3><p>A critical aspect of this endeavor is ensuring that scientific initiatives are closely aligned with the specific requirements of particular diseases, ultimately striving toward the creation of viable products in regenerative medicine.</p><h3>Results</h3><p>Natural biomaterials, including collagen, chitosan, alginate, silk fibroin, and fibrin, closely mimic the native extracellular matrix and provide intrinsic bioactive cues that promote cell adhesion, proliferation, migration, and lineage-specific differentiation. These polymers often present specific motifs that engage cell surface receptors such as integrins, activating signaling pathways central to tissue repair and remodeling, while their hydrophilic and porous architecture enhances nutrient transport and waste removal in three-dimensional constructs. Their degradation is primarily mediated by endogenous enzymes (e.g., collagenases, lysozymes), enabling controlled resorption synchronized with new tissue deposition and thereby reducing the risks of mechanical mismatch, fibrosis, and chronic inflammation. Compared with synthetic polymers such as polylactic acid, polyglycolic acid, and polycaprolactone whose strength, architecture, and hydrolytic degradation rates can be precisely engineered but which often lack inherent bioactivity and may release inflammatory byproducts, natural scaffolds generally exhibit superior biocompatibility and support more effective functional integration in vitro and in vivo.</p><h3>Conclusions</h3><p>The core advantage of using natural biomaterials due to their ability to bridge structural support with biological functionality, and their integration into hybrid constructs with synthetic polymers represents a promising strategy to couple mechanical robustness with biomimetic signaling, accelerating translation toward clinically relevant regenerative therapies.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00933-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147336231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring hydantoin frameworks: synthetic approaches and therapeutic potential 探索氢妥因框架:合成方法和治疗潜力
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-01-30 DOI: 10.1186/s43094-025-00918-z
Nirmala V. Shinde, Vrushali P. Patole, Manoj R. Kumbhare, Harsha Narkhede, Ashwini T. Satalkar, Anushka V. Thube, Sachin K. Bhosale
{"title":"Exploring hydantoin frameworks: synthetic approaches and therapeutic potential","authors":"Nirmala V. Shinde,&nbsp;Vrushali P. Patole,&nbsp;Manoj R. Kumbhare,&nbsp;Harsha Narkhede,&nbsp;Ashwini T. Satalkar,&nbsp;Anushka V. Thube,&nbsp;Sachin K. Bhosale","doi":"10.1186/s43094-025-00918-z","DOIUrl":"10.1186/s43094-025-00918-z","url":null,"abstract":"<div><h3>Background</h3><p>Since its first synthesis in the nineteenth century, hydantoin has emerged as a vital scaffold in drug development, especially for anticonvulsant, antimicrobial, antitumor, and anti-inflammatory agents. Phenytoin, a well-known hydantoin derivative, remains a cornerstone in epilepsy treatment due to its modulation of voltage-gated sodium channels. Beyond this, hydantoin derivatives exhibit diverse biological activities, including anticancer, immunomodulatory, and antimicrobial properties. Synthetic versatility and a broad bioactive profile enhance their pharmaceutical significance.</p><h3>Objective</h3><p>The objective of this review is to provide a comprehensive insights on hydantoin derivatives, highlighting their pharmacological potential, structural diversity, and synthetic approaches. It also explores how substitution patterns and stereochemistry influence their biological activity.</p><h3>Materials and Methods</h3><p>Hydantoin derivatives can be synthesized through conventional methods and advanced techniques, such as microwave-assisted synthesis. Their anticonvulsant properties are typically evaluated using both in vitro and in vivo models. Common in vivo screening includes intraperitoneal administration in maximal electroshock (MES) and subcutaneous pentylenetetrazol (scPTZ)-induced seizure models.</p><h3>Results</h3><p>Studies show that substitution at key positions on the hydantoin ring significantly affects biological activity. Microwave-assisted synthesis often yields more potent derivatives. Some compounds also exhibit anti-inflammatory and anticancer activities, broadening their therapeutic potential.</p><h3>Conclusion</h3><p>Hydantoin derivatives exhibit significant pharmacological potential, driven by their structural versatility and diverse substitution patterns. Enhanced synthetic approaches, such as microwave-assisted methods, improve yield and bioactivity. Their broad spectrum of action, particularly in anticonvulsant, anti-inflammatory, and anticancer domains, underscores their continued relevance in drug development.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00918-z.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146083117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction Note: Antiulcer activity of ethanolic leaf extract of Capparis zeylanica against chemically induced ulcers 撤回注:白头草乙醇叶提取物对化学诱导溃疡的抗溃疡活性
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-01-29 DOI: 10.1186/s43094-026-00936-5
Abhishek Tripathi, Sunil Singh, Alok Mukerjee
{"title":"Retraction Note: Antiulcer activity of ethanolic leaf extract of Capparis zeylanica against chemically induced ulcers","authors":"Abhishek Tripathi,&nbsp;Sunil Singh,&nbsp;Alok Mukerjee","doi":"10.1186/s43094-026-00936-5","DOIUrl":"10.1186/s43094-026-00936-5","url":null,"abstract":"","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00936-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146082521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis of substituted N'-(3-oxo-1,3-diphenylpropyl)isonicotinohydrazide and evaluation of their antimicrobial activities 取代N'-(3-氧-1,3-二苯丙基)异烟碱肼的合成及其抑菌活性评价
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-01-27 DOI: 10.1186/s43094-025-00928-x
Shukhia Sharmin, Md Mizanur Rahman Badal, Md Kabidur Rahman, Md Maniruzzaman, Md Rubel Al-Mamun, Mohammad Abu Yousuf, Md Aminul Haque
{"title":"Synthesis of substituted N'-(3-oxo-1,3-diphenylpropyl)isonicotinohydrazide and evaluation of their antimicrobial activities","authors":"Shukhia Sharmin,&nbsp;Md Mizanur Rahman Badal,&nbsp;Md Kabidur Rahman,&nbsp;Md Maniruzzaman,&nbsp;Md Rubel Al-Mamun,&nbsp;Mohammad Abu Yousuf,&nbsp;Md Aminul Haque","doi":"10.1186/s43094-025-00928-x","DOIUrl":"10.1186/s43094-025-00928-x","url":null,"abstract":"<div><h3>Background</h3><p>Chalcones are versatile intermediates widely used in synthesizing heterocyclic compounds due to their diverse pharmacological potential. ß-amino ketones, derived from chalcones, are valuable in medicinal chemistry as intermediates for bioactive molecules. This study focuses on the synthesis of substituted <i>N</i>'-(3-oxo-1,3-diphenylpropyl)isonicotinohydrazides via an Aza-Michael reaction, using substituted chalcones and isoniazid.</p><h3>Results</h3><p>The synthesized compounds were characterized by spectral data (UV–visible, FTIR, 1H NMR, 13C NMR, and elemental analysis). Antimicrobial activities were evaluated against Gram-positive and Gram-negative bacteria and fungal strains using the standard disk diffusion method. Specifically, compound 5a exhibited a 32 mm zone of inhibition against <i>Panysallium notatum</i> and a 15 mm zone of inhibition against <i>Trichoderma harzianum</i>, which were superior to the standard commercial antifungal agent miconazole (15 mm and 10 mm, respectively).</p><h3>Conclusion</h3><p>The study successfully synthesized and characterized ß-amino ketones derived from substituted chalcones and isoniazid. Among the synthesized compounds, 5a displayed remarkable antifungal activity, compared with the standard antifungal agent, miconazole. This highlights its potential as a lead compound for developing new antifungal agents.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00928-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146082347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling the anti-gout potential of terpenes isolated from Penicillium sp. supported by in silico studies 揭示从青霉菌中分离的萜烯的抗痛风潜力,并得到计算机研究的支持
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-01-22 DOI: 10.1186/s43094-025-00924-1
Abdelrhman M. Mohamed, Shaza H. Aly, Ahmed M. Elissawy, Mohamed A. Elanany, Rakesh K. Bachheti, Abdel Nasser B. Singab
{"title":"Unveiling the anti-gout potential of terpenes isolated from Penicillium sp. supported by in silico studies","authors":"Abdelrhman M. Mohamed,&nbsp;Shaza H. Aly,&nbsp;Ahmed M. Elissawy,&nbsp;Mohamed A. Elanany,&nbsp;Rakesh K. Bachheti,&nbsp;Abdel Nasser B. Singab","doi":"10.1186/s43094-025-00924-1","DOIUrl":"10.1186/s43094-025-00924-1","url":null,"abstract":"<div><h3>Background</h3><p>Genus <i>Penicillium</i> represents one of the most prolific fungi in terms of biosynthesis of bioactive secondary metabolites. This review aims to survey the reported terpenoids isolated from different species of genus <i>Penicillium</i> and virtually screen their potential as xanthine oxidoreductase (XORs) inhibitors via in silico molecular modeling studies.</p><h3>Results</h3><p>More than 140 terpenoidal compounds were included in this study and evaluated for their in silico XOR inhibitory activity. The in silico study revealed that compounds 3-hydroxy-agathic acid (<b>27</b>), agathic acid (<b>28</b>), isopenicin A (<b>86</b>), decaturenol A (<b>108</b>), chermebilaene A (<b>137</b>), and 6-[(2E,6E)-10,11-dihydro-11-hydroxy-farnesyl]- 5,7-dihydroxy-4-methylphthalide (<b>142</b>) exhibit considerable inhibition of XOR potential.</p><h3>Conclusion</h3><p>The in silico XORs inhibition screening study revealed promising candidates from the terpenoidal pool reported from different <i>Penicillium sp</i>., and these candidates can be promoted for further in vitro<i>,</i> in vivo<i>,</i> and preclinical studies to validate the in silico results to support the anti-gout drug pipelines with potential natural products candidates.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00924-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A marvelous hope in the treatment of breast cancer: Moorena producens as an incredible source of bioactive metabolites with a variety of unique selective molecular mechanisms 乳腺癌治疗的巨大希望:Moorena是一种不可思议的生物活性代谢物来源,具有多种独特的选择性分子机制
IF 3
Future Journal of Pharmaceutical Sciences Pub Date : 2026-01-21 DOI: 10.1186/s43094-025-00923-2
Esraa M. Abdelhady, Mona M. Hashem, Mohammed N. A. Khalil, Omar M. Sabry
{"title":"A marvelous hope in the treatment of breast cancer: Moorena producens as an incredible source of bioactive metabolites with a variety of unique selective molecular mechanisms","authors":"Esraa M. Abdelhady,&nbsp;Mona M. Hashem,&nbsp;Mohammed N. A. Khalil,&nbsp;Omar M. Sabry","doi":"10.1186/s43094-025-00923-2","DOIUrl":"10.1186/s43094-025-00923-2","url":null,"abstract":"<div><p>Breast cancer is the most prevalent cause of cancer-related deaths among women worldwide. Patients that get chemotherapy endure severe side effects and develop drug resistance. To optimize the immune system's ability to destroy breast cancer, several strategies have been developed. Natural product-based breast cancer treatments are also getting plenty of attention because of their low toxicity as well as their high efficacy and selectivity. From marine cyanobacteria <i>Moorena producens</i>, about 231 chemicals were discovered and categorized into 66 types. The role of <i>M. producens</i> constituents such as malyngamides, microcolins, dolastatins, apratoxins, apramides, lyngbyatoxins, guineamides, oscillatoxins, and majusculamides in the treatment of breast cancer is thoroughly reviewed in this article, which also highlights related mechanisms of action and potential difficulties. Additionally, it provides recommendations for future research directions.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-025-00923-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146026811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书